Similar research by Downes et al detected endometrial cancer or precursor lesions in 32% of prophylactic hysterectomy specimens from women with LS.69 Unlike patients with BRCA1 and BRCA2 mutations, there are no formal recommendations regarding risk‐reducing gynecologic surgeries for patients with MMR mutations, despite evidence of benefit. This evidence concerns the gene MRC1 and endometrial cancer.